ZYME News and Press, Zymeworks Inc.

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...

2024-07-09 12:12:41 ET Summary Zymeworks Inc. is a Vancouver-based oncology-focused clinical-stage biopharma firm whose lead candidate is advancing on numerous fronts. The company has significant partnership deals with Jazz Pharmaceuticals and BeiGene, Ltd. The company is well...

2024-06-21 09:15:24 ET Summary Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is performing well despite generic Xyrem and Lumryz co...

2024-06-17 14:49:47 ET More on Zymeworks Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data Zymeworks shares sink after company removes CFO Christopher Astle Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript Zymeworks Q1 2024 Earnin...

2024-06-17 10:40:00 ET Summary Shionogi optioned rights for two candidates targeting cochlear synaptopathy, including one that is poised to start a Phase II trial. XtalPi raised US$126.8 million in a Hong Kong IPO, the third-largest Hong Kong IPO of the year. Takeda entered a ...

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...

The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME ). The firm’s ongoing investigation concerns whether Zymeworks and/or certain of its...

2024-05-15 08:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-02 20:04:10 ET Zymeworks Inc. (ZYME) Q1 2024 Earnings Call Transcript May 02, 2024 04:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Ken Galbraith - Chair and CEO Paul Moore - Chief Scientific Officer Conference Call Pa...